Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 804.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,474 shares of the company's stock after acquiring an additional 60,016 shares during the period. GAMMA Investing LLC's holdings in Teva Pharmaceutical Industries were worth $1,037,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. FMR LLC grew its stake in Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after acquiring an additional 19,242,468 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd grew its stake in Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares in the last quarter. Ion Asset Management Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 1.1% in the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company's stock worth $807,766,000 after purchasing an additional 409,778 shares during the period. Lingotto Investment Management LLP lifted its position in shares of Teva Pharmaceutical Industries by 2.6% in the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock worth $599,320,000 after purchasing an additional 688,862 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock worth $203,642,000 after purchasing an additional 489,041 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 target price for the company. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their target price for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Finally, Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Nine research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $24.44.

Insider Transactions at Teva Pharmaceutical Industries

In other news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the sale, the executive vice president now directly owns 9,989 shares of the company's stock, valued at approximately $170,012.78. The trade was a 38.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded up $0.18 during trading on Wednesday, hitting $17.07. The company had a trading volume of 11,691,727 shares, compared to its average volume of 10,237,149. The stock has a fifty day simple moving average of $16.23 and a two-hundred day simple moving average of $17.42. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The firm has a market capitalization of $19.58 billion, a price-to-earnings ratio of -14.84, a price-to-earnings-growth ratio of 0.90 and a beta of 0.60. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The company's revenue for the quarter was up 1.9% on a year-over-year basis. During the same period last year, the firm posted $0.48 earnings per share. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.